Since there's been no additional news from the company regarding the FDA meeting, should we assume that they are meeting with essential FDA employees (would that be the definition of oxymoronic?) and the meeting is going to take place?
The focus around here has been on the FDA meeting, but I'd like to hear some good news about those three remaining MACs. I'd like to say no news is good news, but that isn't the case now. These three MACs are drivers of future revenue growth.
I agree with you. But as we all now, the focus is sometimes in the wrong place. Just like the fact that the injectibles are only 15% of revenue (meaning FDA is not a huge deal) and most of us invested here long term are here because of the non-injectibles - and looking for a suitor like Medtronic, etc. The market, unfortunately, is rarely a rationale place.